Eton Pharmaceuticals, Inc. (ETON) stock
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30521% above fair value
$63.65−0.23 (-0.36%)
Close on Nov 17, 2026Market cap $1.82BP/E 163.2Yield –
Eton Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Eton Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.76M. For fiscal 2025 it was $7.77M, up 138.6% from the year before. The highest annual figure on record is $14.10M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.77M | +138.6% |
| FY2024 | Dec 31, 2024 | $3.26M | -2.0% |
| FY2023 | Dec 31, 2023 | $3.32M | -16.9% |
| FY2022 | Dec 31, 2022 | $4.00M | -35.9% |
| FY2021 | Dec 31, 2021 | $6.24M | -55.8% |
| FY2020 | Dec 31, 2020 | $14.10M | +22.1% |
| FY2019 | Dec 31, 2019 | $11.56M | +105.3% |
| FY2018 | Dec 31, 2018 | $5.63M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $993.00K | -73.2% |
| Q1 FY2026 | Mar 31, 2026 | $1.88M | +61.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.78M | +252.5% |
| Q3 FY2025 | Sep 30, 2025 | $1.11M | -62.6% |
| Q2 FY2025 | Jun 30, 2025 | $3.71M | +470.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.16M | +10.9% |
| Q3 FY2024 | Sep 30, 2024 | $505.00K | -17.9% |
| Q2 FY2024 | Jun 30, 2024 | $2.97M | +164.0% |
| Q1 FY2024 | Mar 31, 2024 | $651.00K | +21.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.05M | +10.9% |
| Q3 FY2023 | Sep 30, 2023 | $615.00K | -17.3% |
| Q2 FY2023 | Jun 30, 2023 | $1.13M | +63.0% |
| Q1 FY2023 | Mar 31, 2023 | $535.00K | -66.9% |
| Q4 FY2022 | Dec 31, 2022 | $944.00K | +38.6% |
| Q3 FY2022 | Sep 30, 2022 | $744.00K | -72.2% |
| Q2 FY2022 | Jun 30, 2022 | $690.00K | -65.3% |
| Q1 FY2022 | Mar 31, 2022 | $1.62M | +82.6% |
| Q4 FY2021 | Dec 31, 2021 | $681.00K | -80.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.68M | -5.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.99M | +23.7% |
| Q1 FY2021 | Mar 31, 2021 | $886.00K | -85.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.40M | +1359.7% |
| Q3 FY2020 | Sep 30, 2020 | $2.83M | -17.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.61M | +11.8% |
| Q1 FY2020 | Mar 31, 2020 | $6.27M | -3.0% |
| Q4 FY2019 | Dec 31, 2019 | $233.00K | -78.9% |
| Q3 FY2019 | Sep 30, 2019 | $3.42M | +121.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.44M | -15.7% |
| Q1 FY2019 | Mar 31, 2019 | $6.47M | +407.5% |
| Q4 FY2018 | Dec 31, 2018 | $1.10M | -29.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.54M | – |
| Q2 FY2018 | Jun 30, 2018 | $1.71M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.27M | – |
| Q3 FY2017 | Sep 30, 2017 | $1.56M | – |
See a number that looks wrong?